Combining Percentage Prostate‐Specific Antigen Reduction and Multiparametric Magnetic Resonance Imaging to Reduce Unnecessary Biopsy After Focal Therapy With High‐Intensity Focused Ultrasound for Prostate Cancer
International Journal of Urology · 2025
DOI: 10.1111/iju.70013 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Urology, 2025. Verfasst von Po-Fan Hsieh und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, China Medical University Hospital, Taichung, Taiwan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Multiparametric Magnetic Resonance Imaging, Prostate-Specific Antigen, Prostate. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
Objectives
To test the feasibility of combining percentage prostate‐specific antigen (PSA) reduction and multiparametric magnetic resonance imaging (mpMRI) to determine the clinical scenario in which follow‐up biopsy could be avoided after focal therapy (FT) with high‐intensity focused ultrasound (HIFU) for prostate cancer.
Methods
We reviewed 90 men treated with FT. Percentage PSA reduction was calculated by PSA nadir within postoperative 6 months. mpMRI was arranged at postoperative 6 months, followed by routine biopsy. Logistic regression analyses were performed to identify predictors for clinically significant prostate cancer (csPC) on follow‐up biopsy. Receiver operating characteristic curve analysis was done to assess the area under the curve (AUC). The diagnostic performance of percentage PSA reduction and mpMRI to predict csPC was also calculated.
Results
Eight patients had csPC recurrence. Percentage PSA reduction and Prostate Imaging–Reporting and Data System (PI‐RADS) ≥ 3 at postoperative 6 months were predictors for csPC ( p = 0.033 and p = 0.02, respectively). The AUC of mpMRI, percentage PSA reduction, and their combination were 0.95, 0.816, and 0.982, respectively. The sensitivity, specificity, positive predictive value, and negative predictive value of PSA reduction < 70% and PI‐RADS ≥ 3 to predict csPC were 87.5%, 69.5%, 21.9%, 98.3%, and 87.5%, 96.3%, 70%, 98.8%, respectively. Using the criteria of PSA reduction < 70% or PI‐RADS ≥ 3 to determine biopsy candidates could avoid 60% of biopsies, without missing csPC.
Conclusion
For patients whose PSA reduction > 70% and PI‐RADS < 3, we suggested avoiding routine biopsy at 6 months after FT with HIFU.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, China Medical University Hospital, Taichung, Taiwan.
- School of Medicine, China Medical University, Taichung, Taiwan.
- Department of Urology, Tokai University School of Medicine, Isehara, Kanagawa, Japan.
ORCID-Profile: Po-Fan Hsieh, Sunao Shoji
Zitieren
APA
Hsieh, P. F., Naruse, J., Yuzuriha, S., Umemoto, T., Huang, C. P., & Shoji, S. (2025). Combining Percentage Prostate‐Specific Antigen Reduction and Multiparametric Magnetic Resonance Imaging to Reduce Unnecessary Biopsy After Focal Therapy With High‐Intensity Focused Ultrasound for Prostate Cancer. International Journal of Urology. https://doi.org/10.1111/iju.70013
Vancouver
Hsieh PF, Naruse J, Yuzuriha S, Umemoto T, Huang CP, Shoji S. Combining Percentage Prostate‐Specific Antigen Reduction and Multiparametric Magnetic Resonance Imaging to Reduce Unnecessary Biopsy After Focal Therapy With High‐Intensity Focused Ultrasound for Prostate Cancer. International Journal of Urology. 2025. doi:10.1111/iju.70013
BibTeX
@article{Hsieh2025,
author = {Hsieh, Po-Fan and Naruse, Jun and Yuzuriha, Soichiro and Umemoto, Tatsuya and Huang, Chi-Ping and Shoji, Sunao},
title = {Combining Percentage Prostate‐Specific Antigen Reduction and Multiparametric Magnetic Resonance Imaging to Reduce Unnecessary Biopsy After Focal Therapy With High‐Intensity Focused Ultrasound for Prostate Cancer},
journal = {International Journal of Urology},
year = {2025},
doi = {10.1111/iju.70013}
}
EUVIMED